Search
EHA 2025: CEO Jonathan Dickinson discusses Innate Pharma's NK cell engager platform (ANKET), recent ASCO data for Lacutamab, and other program updates
He describes Innate's NK cell platform and covers programs targeting CD20, CD123, BCMA, and B7-H3. Plus Lacutamab data, updates on the...
Jun 13
ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs
Jonathan Dickinson describes what appealed to him about Innate. He discusses the pipeline, including ASH data from the lead program...
Dec 7, 2024
Innate Pharma's Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology
Hervé Brailly covers lacutamab, monalizumab, the company's NK engager programs, and more.
Sep 6, 2024
.png){kind=logo}
